GENE ONLINE|News &
Opinion
Blog

2025-11-29|

Study in Northern Ghana Finds Prematurity and Low Birth Weight as Key Risk Factors for Neonatal Jaundice

by GOAI
Share To

A recent study conducted at a teaching hospital in Northern Ghana has examined the incidence and risk factors associated with neonatal jaundice, a condition that continues to pose significant challenges in pediatric health care, particularly in developing regions. The findings highlight key factors contributing to the prevalence of neonatal jaundice in the area, offering valuable data for medical professionals and policymakers addressing this issue.

The research identifies several risk factors linked to the development of neonatal jaundice, including prematurity, low birth weight, and inadequate prenatal care. The study also notes that delayed initiation of breastfeeding and certain maternal health conditions may increase the likelihood of newborns developing the condition. These findings underscore the importance of early detection and intervention strategies to manage neonatal jaundice effectively. The study provides critical insights into how regional healthcare systems can better address this common yet potentially serious condition affecting newborns.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 29, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top